Key result
Unprovoked VTE is linked to ~98% higher recurrence risk vs. provoked VTE with rivaroxaban.
Why the study?
Does unprovoked VTE status compared to provoked VTE status affect the risk of symptomatic VTE recurrence and major bleeding in patients with acute VTE treated with rivaroxaban?
Cohort (n=945)
Yes
Does unprovoked VTE status compared to provoked VTE status affect the risk of symptomatic VTE recurrence and major bleeding in patients with acute VTE treated with rivaroxaban?
Patients with unprovoked VTE treated with rivaroxaban have nearly double the rate of VTE recurrence compared to those with provoked VTE despite longer treatment duration, warranting careful consideration before discontinuing anticoagulation, especially in those with BMI ≥25 kg/m2.
Answers are grounded in this paper and cite their sources.
May inform anticoagulation duration decisions in rivaroxaban-treated VTE; leaves open prospective validation of unprovoked status.
Background The efficacy and safety of direct oral anticoagulants (DOACs) in patients with unprovoked venous thromboembolism (VTE) remain unclear. Methods and Results In this subanalysis of the J’xactly study, a multicenter prospective observational study, we evaluated the safety and effectiveness of rivaroxaban in patients with acute VTE according to unprovoked (n=388) or provoked (n=557) VTE status. Median follow-up was 21.2 months. Compared with patients in the provoked group, patients in the unprovoked group were younger, less likely to be female, and had higher body weight. The incidence of symptomatic VTE recurrence was significantly higher in the unprovoked than provoked VTE group (3.54% vs. 1.77% per patient-year; P=0.032). There was no significant difference in the incidence of major bleeding events between rivaroxaban-treated patients with unprovoked and provoked VTE (2.31% vs. 3.75% per patient-year; P=0.289). Although the proportion of patients with a body mass index (BMI) ≥25 kg/m2 who were non-users of antiplatelet agents was higher in the unprovoked VTE group, there was no interaction effect (BMI: 4.58% vs. 1.55% per patient-year [P=0.040; P for interaction=0.361]; concomitant antiplatelet agent non-users: 3.65% vs. 1.72% per patient-year [P=0.028; P for interaction=0.627]). Conclusions This subanalysis suggests the safety and effectiveness of rivaroxaban in patients with unprovoked VTE. In such patients, DOAC discontinuation should be considered carefully, particularly in those not using antiplatelet agents and those with a high BMI.
No takes yet. Share an insight, caveat, or question.
Hisatake et al. (2022) conducted a cohort in Acute venous thromboembolism (deep vein thrombosis, pulmonary embolism, or both) (n=945). Unprovoked VTE status (treated with oral rivaroxaban) vs. Provoked VTE status (treated with oral rivaroxaban) was evaluated on Recurrence or aggravation of symptomatic venous thromboembolism (VTE) (HR 1.98, 95% CI 1.05-3.76, p=0.032). Unprovoked VTE was associated with a higher rate of symptomatic VTE recurrence than provoked VTE in rivaroxaban-treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: